Jade Biosciences
JBIO
77 hedge funds and large institutions have $841M invested in Jade Biosciences in 2024 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 18 increasing their positions, 23 reducing their positions, and 4 closing their positions.
350% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 4
32% more capital invested
Capital invested by funds: $638M → $841M (+$204M)
20% more funds holding
Funds holding: 64 → 77 (+13)
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
0.01% more ownership
Funds ownership: 2.91% → 2.92% (+0.01%)
22% less repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 23
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$9.46M |
| 2 |
IC
Ikarian Capital
Dallas,
Texas
|
+$8.03M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
+$4.36M |
| 4 |
Ensign Peak Advisors
Salt Lake City,
Utah
|
+$3.06M |
| 5 |
SCM
Superstring Capital Management
New York
|
+$2.41M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VPC
Vestal Point Capital
New York
|
-$9.05M |
| 2 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$5.74M |
| 3 |
O
OrbiMed
New York
|
-$4.18M |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$3.27M |
| 5 |
PBA
Paradigm Biocapital Advisors
New York
|
-$3.24M |
JBIO Hedge Fund Activity: Q1 2024 in Review
77 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Jade Biosciences (JBIO) for Q1 2024, worth a combined $841M — up 32% from $638M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new JBIO positions and 4 closed out — a net gain of 14 holders — while 18 added to existing stakes and 23 trimmed.
The largest buyer was Eventide Asset Management, adding an estimated $9.46M. The largest seller was Vestal Point Capital, exiting entirely with an estimated $9.05M sold.
- 77 institutional investors held Jade Biosciences (JBIO) as of Q1 2024, up from 64 in Q4 2023.
- Funds reported $841M of Jade Biosciences stock for Q1 2024, up 32% quarter-over-quarter.
- 18 funds opened new Jade Biosciences positions in Q1 2024 and 4 closed out, a net change of +14 holders.
- The largest Jade Biosciences buyer in Q1 2024 was Eventide Asset Management, an estimated $9.46M added.
- The largest Jade Biosciences seller in Q1 2024 was Vestal Point Capital, an estimated $9.05M sold.
Based on aggregated 13F filings for Q1 2024.